PENSACOLA, FL, USA and SHANGHAI, CHINA, August 25, 2025 – Ametris, a global digital health solutions provider transforming real-world patient data into validated clinical evidence, and Luca Healthcare, a leader in using AI algorithms and machine learning to develop predictive healthcare solutions, today announced a strategic partnership aimed at significantly enhancing the adoption and deployment of Digital Health Tools (DHTs) in clinical trials, particularly within the rapidly evolving US and Chinese markets.
This collaboration comes at a pivotal time, as clinical trial trends in both the US and China show a strong inclination towards digital transformation, driven by the need for greater efficiency, patient centricity, and real-world data collection. The integration of advanced digital health technologies is proving crucial in streamlining drug development, reducing costs, and ultimately bringing life-changing therapies to patients faster.
"We are incredibly excited to partner with Luca Healthcare to expand the reach and impact of our digital health solutions," said Jeremy Wyatt, CEO of Ametris. "The landscape of clinical trials is rapidly evolving, with a clear demand for more efficient and patient-friendly approaches. By combining Ametris' expertise in validated real-world data collection with Luca's innovative AI-driven solutions and strong presence in the Chinese and Asian markets, we are poised to accelerate drug development for pharmaceutical companies in both the US and China, ultimately benefiting patients worldwide."
Under this strategic partnership, Luca Healthcare will help expand Ametris’ existing business in China and Asia by integrating Ametris’ wearable technologies to pharmaceutical partners, enabling Ametris to offer a full range of Decentralized Clinical Trial (DCT) products and services for the Chinese and Asian markets. Concurrently, Ametris will support Luca’s business expansion in the US, enabling Luca to offer clinically validated AI solutions in both clinical trials and as digital companions.
"Our mission at Luca Healthcare is to provide affordable, accessible, and clinically validated digital health solutions," said Echo Chen, Ph.D., CEO of Luca Healthcare. "This partnership with Ametris is a significant step forward in achieving that mission on a global scale. By integrating Ametris' robust digital health tools with our AI-driven predictive capabilities, we can offer a comprehensive suite of solutions that will accelerate clinical trials in both the US and China, addressing critical needs in drug development and improving patient outcomes."
About Ametris
Founded in 2004, Ametris (formerly ActiGraph) is a global digital health solutions provider transforming real-world patient data into validated clinical evidence. Our end-to-end platform combines advanced wearables, regulatory-aligned analytics, and expert scientific support to simplify every phase of a clinical trial—from study design to submission. Backed by two decades of experience and a collaborative approach, Ametris empowers research teams to run smarter trials, reduce patient burden, and accelerate therapeutic innovation.
About Luca Healthcare
Luca Healthcare is a leader in using AI algorithms and machine learning to develop predictive healthcare solutions. The company is dedicated to providing affordable, accessible, and clinically validated software-based screening, tracking, management, and treatment solutions to a wider patient population through digital innovation and global partnerships.